Zhejiang Huahai Pharmaceutical received a warning letter from the FDA for issues related to impurity control, change control and cross-contamination from one manufacturing line to another. These issues are connected to nitrosamine impurities found in valsartan-containing medications, which the company supplies to Mylan.

Full Story:
Seeking Alpha

Related Summaries